Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension

Gastroenterology

Volumn 120, Issue 1, 2001, Pages 161-169

  Escorsell, Àngels ^a   Bandi, Juan Carlos ^a   Andreu, Victòria ^a   Moitinho, Eduardo ^a   García Pagán, Joan Carles ^a   Bosch, Jaume ^a   Rodés, Joan ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; OCTREOTIDE; PLACEBO;

ADULT; AGED; ARTICLE; AZYGOS VEIN; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESOPHAGUS VARICES; FEMALE; GLUCAGON BLOOD LEVEL; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; TACHYPHYLAXIS;

EID: 0035165156     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.20892     Document Type: Article

References (28)

1. Octreotide
2. Development of analogues: Successes and failures
3. Hemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis
4. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension
5. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis
6. Effect of octreotide on systemic, central and splanchnic hemodynamics in cirrhosis
7. Effects of a somatostatin analogue SMS 201-995 on hepatic hemodynamics in the pig and on intravariceal pressure in man
8. Assessment of variceal pressure by continuous non-invasive endoscopic registration: A placebo controlled evaluation of the effect of terlipressin and octreotide
9. The effect of somatostatin and octreotide on intravascular esophageal variceal pressure in patients with cirrhosis
10. Short-term effect of octreotide on intraesophageal variceal pressure: A double-blind placebo controlled study
11. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: A double-blind, placebo-controlled study
12. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension
13. Effects of octreotide on postprandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis
14. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-Doppler study
15. Cardiovascular effects of octreotide in patients with hepatic cirrhosis
16. Hemodynamic evaluation of the patient with portal hypertension
17. Measurement of hepatic blood flow, hepatic extraction and intrinsic clearance of indocyanine green in patients with cirrhosis. Comparison of a non-invasive pharmacokinetic method with measurement using hepatic vein catheterization
18. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation
19. Pharmacokinetics of S.M.S. 201-995 in healthy subjects
20. Pharmacological therapy of portal hypertension: An evidence-based approach
21. Sclerotherapy with or without octreotide for acute variceal bleeding
22. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation
23. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin
24. Effects of somatostatin in patients with portal hypertension
25. Effects of somatostatin on intestinal circulation and oxygen consumption
26. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis
27. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor
28. Somatostatin receptor desensitization in NG108-15 cells. A consequence of receptor sequestration